Telomir-Zn Shows Promise in Wilson’s Disease Study

Telomir Pharmaceuticals (NASDAQ: TELO) has announced a significant scientific breakthrough with the publication of peer-reviewed preclinical data in Advances in Redox Research. The study shows that Telomir-Zn, the company's lead small-molecule therapeutic, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. Key findings include reduced oxidative stress, lower hepatic copper burden, and improved liver function markers. These results not only support the biological activity of Telomir-Zn in Wilson’s disease but also expand the company’s scientific validation as it advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation.

Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics that target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company's lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. The latest news and updates relating to TELO are available in the company’s newsroom at https://ibn.fm/TELO.

InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication, distributed this news. IW is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With a seasoned team of contributing journalists and writers, IW brings its clients unparalleled recognition and brand awareness.